(Photo Courtesy: www.entrepreneur.com)
While cellular immunotherapies, which encompass dendritic cell therapy and chimeric antigen receptor T-cell (CAR-T) therapy, are expected to show promising results in combination treatments in the next few years, they are unlikely to make a significant impact on the immuno-oncology market in the short term according to research and consulting firm GlobalData.
The company's latest report states that recent advancements in the field of adoptive T-cell therapy have created much excitement surrounding CAR-T therapy as a potential cure for a variety of cancers.
Indeed, the treatment hit the headlines in February 2016 after a preliminary clinical trial found that six out of the seven patients treated with CAR-T therapy were in complete remission.
Dr Dan Roberts, GlobalData's Senior Analyst covering Oncology and Hematology, says: "Although the immuno-oncology space will be dominated by immune checkpoint inhibitors, which GlobalData forecasts to achieve sales of $24 billion by 2024, cellular immunotherapies and cancer vaccines will continue to be pursued, despite past failures."
Novartis' CAR-T therapy, CTL019, will most likely be the first of its kind to be approved for patients with acute leukemia, giving it a head start in the segment.